Navigation Links
ASA404 in Medical Technology

Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial

LONDON, 12 July 2007 - Cancer drug developer Antisoma plc (LSE: ASM, US OTC: ATSMY) today announces new data from its phase II trial of ASA404 in recurrent, platinum-sensitive ovarian cancer. This trial compares patients receiving ASA404 plus chemotherapy (n=37) with patients receiving chemotherap...

Strength and Innovation of Novartis Oncology Products and Pipeline With Potential to Improve Patient Treatment Demonstrated by More Than 170 Abstracts at ASCO Annual Meeting

...squamous and non-squamous non-small cell lung cancer patients receiving asa404 (Abstract #8072: Sunday, June 1, 2008; 2:00 PM-6:00 PM CDT). Novartis...with Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML). asa404 is an investigational small-molecule Tumor-VDA that selectively disrupts ex...
ASA404 in Biological Technology

New Report Just Published: World Prostate Cancer Therapeutics Market Report

...in Prostate Cancer II-53 Isis and OncoGenex Reveals Positive results of OGX-011 Molecule in HRPC II-53 Antisoma Completes Phase 2 Study of asa404 in Prostate Cancer II-53 Cougar Conducts Phase I/II Clinical Trials on CB7630 in Patients with Prostate Cancer II-54 Ambrilia Unveils Resu...
ASA404 in other areas

Vadimezan - Wikipedia, the free encyclopedia

Vadimezan or ASA404 is a tumor-vascular disrupting agent (tumor-VDA) that attacks the blood supply of a cancerous tumor to cause tumor regression.

Novartis Oncology Research: ASA404 For Lung Cancer

Read information about ASA404, a Novartis Oncology investigational cancer treatment that disrupts established tumor vasculature, inhibiting tumor blood flow and ...

ASA404 Vascular Disrupting Agent for Solid Tumours - Drug Development ...

Project on the ASA404 vascular disrupting agent for solid tumours by Antisoma and Novartis. ... Novartis subsequently acquired worldwide rights to ASA404 in 2007. ...

Positive data on Antisoma's ASA404 presented at ASCO | Reuters

LONDON, UK, Jun 01 (MARKET WIRE) -- London, UK, and Chicago, IL, 1 June 2008 - Antisoma (LSE: ASM; USOTC:ATSMY) announces that two presentations supporting ASA404 ...

starting a Phase III trial for the drug, ASA404

ASA404 ... Novel mechanism of action of ASA404 disrupts existing blood supply to tumors ... ASA404 is one of six novel oncology compounds Novartis is developing for ...

ATTRACT Clinical Trial – Antivascular Targeted Therapy: Researching ...

Learn about ATTRACT clinical trial from Novartis Oncology, and investigational cancer treatment: Antivascular Targeted Therapy: Researching ASA404 in Cancer Treatment.
Other Tags
(Date:7/31/2015)... ... July 31, 2015 , ... Easter Seals Southern Georgia’s Heels & Wheels Duathlon & Triathlon will ... will be 7:30 AM. The duathlon is a 2 mile run, 13 mile bike ride, ... Lake, a 13 mile bike, and a 3 mile run. Heels & Wheels is ...
(Date:7/31/2015)... ... 2015 , ... Intellitec Solutions announced today they have expanded ... GP for a senior living facility in Maine. Having achieved recognition as a ... 16 states. This further expansion was again a factor of the firm’s success ...
(Date:7/31/2015)... TN (PRWEB) , ... July 31, 2015 , ... ... Tenn. has launched a Balloon Sinuplasty website to inform potential Nashville area ... a questionnaire that can be used to determine if someone is a good ...
(Date:7/30/2015)... ... July 31, 2015 , ... When responsible for the care ... out-of-reach. The questions race through your mind: What happens if mom falls? Who will ... overwhelmed and cancel your plans. , But not taking time away from caregiving responsibilities ...
(Date:7/30/2015)... Church, VA (PRWEB) , ... July 31, 2015 ... ... Manufacturing Floor:, Reduce Errors By 50% or More, **Presented by FDAnews and Ginette ... Dr. Ginette Collazo, a 15 year veteran of helping drug, biologic and device ...
Breaking Medicine News(10 mins):Health News:Heels & Wheels for Megan's House Set for Saturday August 22, 2015 in Waycross, Georgia 2Health News:Intellitec Solutions Expands Long term Care ERP Offerings to Maine 2Health News:Nashville Otolaryngologist Dr. David Gilpin Launches Balloon Sinuplasty Website 2Health News:Nashville Otolaryngologist Dr. David Gilpin Launches Balloon Sinuplasty Website 3Health News:Aging Life Care Association™ Experts Offer Tips for Caregivers in Need of Vacation Time 2Health News:Aging Life Care Association™ Experts Offer Tips for Caregivers in Need of Vacation Time 3Health News:FDAnews Announces — Reduce Human Error on the Drug and Device Manufacturing Floor: Reduce Errors By 50% or More Workshop, Sept. 16-17, 2015 2Health News:FDAnews Announces — Reduce Human Error on the Drug and Device Manufacturing Floor: Reduce Errors By 50% or More Workshop, Sept. 16-17, 2015 3Health News:FDAnews Announces — Reduce Human Error on the Drug and Device Manufacturing Floor: Reduce Errors By 50% or More Workshop, Sept. 16-17, 2015 4
(Date:7/30/2015)... 2015 Cellecta, Inc., a U.S.-based provider ... and biomarker discovery, announced the release of its ... all human protein coding genes. CRISPR technology enables ... gene,s function. Cellecta,s new Human Whole Genome CRISPR ... so that researchers can investigate in a single ...
(Date:7/23/2015)... (NASDAQ: AWRE ), a leading supplier of biometrics software ... ended June 30, 2015.  Revenue for the ... 33% compared to $6.8 million in the same quarter last ... $0.3 million, or $0.01 per diluted share, which compared to ... period a year ago.  Lower revenue and ...
(Date:7/21/2015)... OXFORD, Connecticut , July 21, 2015 /PRNewswire/ ... the "Company"), a biometric authentication company focused on ... the Wocket® smart wallet, announces that it has ... Tokenization System and Method. This ... that not only authorizes an account, but also ...
Breaking Biology News(10 mins):CELLECTA, INC. Announces Launch of Human Whole Genome CRISPR Knockout Library 2Aware, Inc. Reports Second Quarter 2015 Financial Results 2Aware, Inc. Reports Second Quarter 2015 Financial Results 3Aware, Inc. Reports Second Quarter 2015 Financial Results 4Aware, Inc. Reports Second Quarter 2015 Financial Results 5Aware, Inc. Reports Second Quarter 2015 Financial Results 6NXT-ID Patents Personalized Tokenized Payments for Next Generation Secure Payment Technology 2NXT-ID Patents Personalized Tokenized Payments for Next Generation Secure Payment Technology 3NXT-ID Patents Personalized Tokenized Payments for Next Generation Secure Payment Technology 4
Other Contents